"Mayer, Ji\u0159\u00ED" . . "1802-4475" . "RIV/00216224:14110/13:00072779" . . "Vesel\u00E1, Pavla" . "mantle cell lymphoma; cyclin D1; t(11; 14); SOX-11; NOTCH1"@en . . "14110" . "I" . "New perspectives in the pathogenesis and diagnosis of mantle cell lymphoma"@en . "Nov\u00E9 perspektivy v patogenezi a diagnostice lymfomu z pl\u00E1\u0161\u0165ov\u00FDch bun\u011Bk (mantle cell lymfomu)"@cs . "RIV/00216224:14110/13:00072779!RIV14-MSM-14110___" . . "Mantle cell lymphoma represents about 7-8 % of all non-Hodgkin lymphomas. This entity is characterized by a combination of mostly aggresive clinical course and frequent relapses. The prognosis remains poor with a median overall survival of 4-5 years. It is hypothesized that a coincidence of several pathological events is necessary for arise of clinically manifest MCL. The primary oncogenic mechanism is considered to be a chromosomal translocation t(11;14) with juxtaposition of BCL1 gene to the IGH gene. It results in overexpression of cyclin D1, which positively affects the G1-S transition of cell cycle. Another frequent mutation is a deletion 11q22-23 leading to the inactivation of the ATM gene responsible for the DNA damage response. In such case, the genomic instability and subsequently the frequency of another mutations is highly increased."@en . "New perspectives in the pathogenesis and diagnosis of mantle cell lymphoma"@en . . "Nov\u00E9 perspektivy v patogenezi a diagnostice lymfomu z pl\u00E1\u0161\u0165ov\u00FDch bun\u011Bk (mantle cell lymfomu)" . "6"^^ . . . . . "Mantle cell lymfom (MCL) neboli lymfom z pl\u00E1\u0161\u0165ov\u00FDch bun\u011Bk pat\u0159\u00ED mezi vz\u00E1cn\u011Bj\u0161\u00ED B-lymfoproliferace s pod\u00EDlem asi 7\u20138 % na celkov\u00E9m mno\u017Estv\u00ED v\u0161ech nehodgkinov\u00FDch lymfom\u016F. Klinicky se MCL vyzna\u010Duje neblahou kombinac\u00ED vlastnost\u00ED indolentn\u00EDch (rekurentn\u00ED pr\u016Fb\u011Bh) a agresivn\u00EDch (vysok\u00E1 prolifera\u010Dn\u00ED aktivita, chemorezistence) lymfom\u016F. Progn\u00F3za onemocn\u011Bn\u00ED z\u016Fst\u00E1v\u00E1 st\u00E1le neuspokojiv\u00E1 s medi\u00E1nem p\u0159e\u017Eit\u00ED 4\u20135 let. V sou\u010Dasn\u00E9 dob\u011B se p\u0159edpokl\u00E1d\u00E1, \u017Ee pro vznik klinicky manifestn\u00EDho MCL je nutn\u00FD soub\u011Bh n\u011Bkolika patologick\u00FDch ud\u00E1lost\u00ED na genov\u00E9 \u00FArovni. Nezbytn\u00FDm p\u0159edpokladem je porucha regulace bun\u011B\u010Dn\u00E9ho cyklu \u0159\u00EDzen\u00E9 cyklinem D1, za dal\u0161\u00ED krok se pova\u017Euje defekt v bun\u011B\u010Dn\u00E9 odpov\u011Bdi na po\u0161kozen\u00ED DNA. Prvotn\u00ED a z\u00E1sadn\u00ED genovou p\u0159estavbou je u MCL pravd\u011Bpodobn\u011B translokace t(11;14), p\u0159i n\u00ED\u017E vznik\u00E1 patologick\u00FD fuzn\u00ED gen BCL1/IGH. Produktem t\u00E9to p\u0159estavby je nadm\u011Brn\u00E1 produkce cyklinu D1, kter\u00E1 v\u0161ak ke vzniku malign\u00EDho lymfomu sama o sob\u011B nesta\u010D\u00ED. U MCL je tak\u00E9 \u010Dast\u00E1 delece 11q22\u201323." . "92257" . "Mantle cell lymfom (MCL) neboli lymfom z pl\u00E1\u0161\u0165ov\u00FDch bun\u011Bk pat\u0159\u00ED mezi vz\u00E1cn\u011Bj\u0161\u00ED B-lymfoproliferace s pod\u00EDlem asi 7\u20138 % na celkov\u00E9m mno\u017Estv\u00ED v\u0161ech nehodgkinov\u00FDch lymfom\u016F. Klinicky se MCL vyzna\u010Duje neblahou kombinac\u00ED vlastnost\u00ED indolentn\u00EDch (rekurentn\u00ED pr\u016Fb\u011Bh) a agresivn\u00EDch (vysok\u00E1 prolifera\u010Dn\u00ED aktivita, chemorezistence) lymfom\u016F. Progn\u00F3za onemocn\u011Bn\u00ED z\u016Fst\u00E1v\u00E1 st\u00E1le neuspokojiv\u00E1 s medi\u00E1nem p\u0159e\u017Eit\u00ED 4\u20135 let. V sou\u010Dasn\u00E9 dob\u011B se p\u0159edpokl\u00E1d\u00E1, \u017Ee pro vznik klinicky manifestn\u00EDho MCL je nutn\u00FD soub\u011Bh n\u011Bkolika patologick\u00FDch ud\u00E1lost\u00ED na genov\u00E9 \u00FArovni. Nezbytn\u00FDm p\u0159edpokladem je porucha regulace bun\u011B\u010Dn\u00E9ho cyklu \u0159\u00EDzen\u00E9 cyklinem D1, za dal\u0161\u00ED krok se pova\u017Euje defekt v bun\u011B\u010Dn\u00E9 odpov\u011Bdi na po\u0161kozen\u00ED DNA. Prvotn\u00ED a z\u00E1sadn\u00ED genovou p\u0159estavbou je u MCL pravd\u011Bpodobn\u011B translokace t(11;14), p\u0159i n\u00ED\u017E vznik\u00E1 patologick\u00FD fuzn\u00ED gen BCL1/IGH. Produktem t\u00E9to p\u0159estavby je nadm\u011Brn\u00E1 produkce cyklinu D1, kter\u00E1 v\u0161ak ke vzniku malign\u00EDho lymfomu sama o sob\u011B nesta\u010D\u00ED. U MCL je tak\u00E9 \u010Dast\u00E1 delece 11q22\u201323."@cs . . "3" . "Jan\u00EDkov\u00E1, Andrea" . "Nov\u00E9 perspektivy v patogenezi a diagnostice lymfomu z pl\u00E1\u0161\u0165ov\u00FDch bun\u011Bk (mantle cell lymfomu)" . "4"^^ . "CZ - \u010Cesk\u00E1 republika" . . "\u0160\u00E1lek, David" . . . . . "3"^^ . "Nov\u00E9 perspektivy v patogenezi a diagnostice lymfomu z pl\u00E1\u0161\u0165ov\u00FDch bun\u011Bk (mantle cell lymfomu)"@cs . "Onkologie" . . . . "[73E66A7C12BA]" . . . "7" .